The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes
Open accessAbstract
OBJECTIVE—Ruboxistaurin selectively inhibits protein kinase C-β and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans. RESEARCH DESIGN AND METHODS—A randomized, double-blind, placebo-controlled, multicenter, pilot study was performed to evaluate the effects of 32 mg/day ruboxistaurin for 1 year in persons (n = 123) with type 2 diabetes and persistent albuminuria (albumin-to-creatinine ratio [ACR] 200-2,000 mg/g), despite therapy with renin-angiotensin system inhibitors. The primary end point was a change in the ACR. Estimated glomerular filtration rate (eGFR) (four-component equation from the Modification of Diet in Renal Disease study) was also calculated. RESULTS—At baseline, urinary ACR was 764 ± 427 mg/g (means ± SD), and eGFR was 70 ± 24 ml/min per 1.73 m2. Systolic and diastolic blood pressures were 135 ± 14 and 75 ± 9 mmHg, respectively. HbA1c was 8.0 ± 1.2%. After 1 year, urinary ACR decreased significantly (−24 ± 9%) in participants treated with ruboxistaurin (P = 0.020) and nonsignificantly (−9 ± 11%) in the placebo group (P = 0.430). The ACR-lowering effect of ruboxistaurin appeared by 1 month. eGFR did not decline significantly in the ruboxistaurin group (−2.5 ± 1.9 ml/min per 1.73 m2) (P = 0.185), whereas the placebo group lost significant eGFR over 1 year (−4.8 ± 1.8 ml/min per 1.73 m2) (P = 0.009). Between-group differences for changes in ACR and eGFR were not statistically significant, but this pilot study was underpowered to determine such differences. CONCLUSIONS—In persons with type 2 diabetes and nephropathy, treatment with ruboxistaurin reduced albuminuria and maintained eGFR over 1 year. Ruboxistaurin may add benefit to established therapies for diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 3×
“In studies of ARBs for persons with type 2 diabetes and nephropathy, the relative risk reduction for renal outcomes was 20% (6,7).”
BackgroundResultThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Bakris, G. L., Williams, M., Dworkin, L., Elliott, W. J., Epstein, M., Toto, R., Tuttle, K., Douglas, J., Hsueh, W., & Sowers, J. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.16225 · Cited by 1,411
Self-citationAmelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor
Ishii, H., Jirousek, M. R., Koya, D., Takagi, C., Xia, P., Clermont, A., Bursell, S.-E., Kern, T. S., Ballas, L. M., Heath, W. F., et al. (1996) · Science · doi:10.1126/science.272.5262.728 · Cited by 1,103
(2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.10.006 · Cited by 1,080
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
Barnett, A. H., Bain, S. C., Bouter, P., Karlberg, B., Madsbad, S., Jervell, J., & Mustonen, J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042274 · Cited by 910
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750
Inoguchi, T., Battan, R., Handler, E., Sportsman, J. R., Heath, W., & King, G. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11059 · Cited by 740
Pedrini, M. T., Levey, A. S., Lau, J., Chalmers*, T. C., & Wang, P. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-7-199604010-00002 · Cited by 496
KOYA, D., HANEDA, M., NAKAGAWA, H., ISSHIKI, K., SATO, H., MAEDA, S., SUGIMOTO, T., YASUDA, H., KASHIWAGI, A., WAYS, D. K., et al. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.3.439 · Cited by 427
Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy
Hansen, H. P., Tauber-Lassen, E., Jensen, B. R., & Parving, H.-H. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00421.x · Cited by 331
Standards of Medical Care for Patients With Diabetes Mellitus
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s33 · Cited by 264
Kelly, D. J., Zhang, Y., Hepper, C., Gow, R. M., Jaworski, K., Kemp, B. E., Wilkinson-Berka, J. L., & Gilbert, R. E. (2003) · Diabetes · doi:10.2337/diabetes.52.2.512 · Cited by 166
Tuttle, K. R., & Anderson, P. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00741-8 · Cited by 91
Self-citation
Cited by
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Self-citationThomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment
Samsu, N. (2021) · BioMed Research International · doi:10.1155/2021/1497449 · Cited by 1,001
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
Geraldes, P., & King, G. L. (2010) · Circulation Research · doi:10.1161/circresaha.110.217117 · Cited by 985
Vascular Complications of Diabetes: Mechanisms of Injury and Protective Factors
Rask-Madsen, C., & King, G. L. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.11.012 · Cited by 846
Metadata
- Authors
- Tuttle, K. R., Bakris, G. L., Toto, R. D., McGill, J. B., Hu, K., & Anderson, P. W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2005-11-01
- Volume
- 28
- Issue
- 11
- Pages
- 2686-2690
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2167764610
- Cited by
- 300
- References
- 20
- FWCI
- 17.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.